


USSN 10/662,493

CT2752NP

Amendments to the Claims

1. (previously amended) A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

A¹ and A² are each independently C₁₋₄alkylene or a bond;

A³ is a bond, C₁₋₄alkylene or C₁₋₄alkylidene;

A⁴ is C₁₋₄alkylene or a bond and is attached to X, X¹ or X²;

X, X^1, X^2 and X^3 are independently C or CH;

J is C₁₋₄alkyl;

p is 0 or 1;

R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C₁₋₄alkyl or C₁₋₄alkyl-N(H)C(O)O-;

said C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy, indolyl or halo;

wherein said indolyl is optionally substituted by
halo or cyano;

USSN 10/662,493

CT2752NP

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano;

or wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl;

R³ is H or C₁₋₄alkyl;

m is 0 or 1;

R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro, C₁₋₃alkyl or C₁₋₃perfluoroalkyl;

wherein said R⁴ or R⁵ may be independently attached to G¹, X, X¹, X² or X³;

n is 0 or 1;

G is N, O or S;

G¹ is N, C or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both R⁴ and R⁵ are not attached to the same of said G¹, X, X¹, X² or X³;

USSN 10/662,493

CT2752NP

if G is O or S, then m is 0;

if G is N, then m is 1;

if R₁ is C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R₂ is H or C₁₋₃alkyl;

if R₂ is C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R₁ is H or C₁₋₃alkyl;

if -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl, then p is 0;

if R¹ is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A¹, then A¹ is C₂₋₄alkylene;

if R² is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A², then A² is C₂₋₄alkylene;

if R¹ is N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are

USSN 10/662,493

CT2752NP

optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano,
then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

if R⁴ or R⁵ are attached to G¹, then G¹ is C;

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C.

2. (original) A compound according to claim 1 wherein p is 0.
3. (original) A compound according to claim 1 wherein G is N and G¹ is CH.
4. (original) A compound according to claim 1 wherein G is S and G¹ is CH.
5. (original) A compound according to claim 1 wherein G is N and G¹ is N.
6. (original) A compound according to claim 1 wherein G is S and G¹ is N.
7. (original) A compound according to claim 1 wherein G is O and G¹ is N.
8. (original) A compound according to claim 1 wherein R¹ is methyl and R² is methyl.
9. (original) A compound according to claim 1 wherein R¹ is H and R² is C₃₋₆cycloalkyl wherein said C₃₋₆cycloalkyl is substituted with indolyl and wherein said indolyl is optionally substituted by halo or cyano.
10. (original) A compound according to claim 1 wherein A¹ is a bond, R¹ is methyl, A² is a bond and R² is methyl.

USSN 10/662,493

CT2752NP

11. (original) A compound according to claim 1 wherein R^3 is H and m is 1.
12. (original) A compound according to claim 1 wherein R^3 is methyl and m is 1.
13. (original) A compound according to claim 1 wherein R^4 and R^5 are halo.
14. (original) A compound according to claim 1 wherein R^4 is C_{1-3} alkyl and is attached to G^1 .
15. (original) A compound according to claim 1 wherein R^4 is C_{1-3} perfluoroalkyl and is attached to G^1 .
16. (original) A compound according to claim 1 wherein R^4 is hydrogen.
17. (original) A compound according to claim 1 wherein R^4 is fluoro.
18. (original) A compound according to claim 1 wherein R^4 is cyano.
19. (original) A compound according to claim 1 wherein R^4 and R^5 are each fluoro.
20. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.
21. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *cis* configuration to the hydrogen atom attached to E.
22. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S.
23. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of R.
24. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of S.
25. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of R.
26. (original) A compound according to claim 1 wherein A^3 is C_{1-4} alkylene.
27. (original) A compound according to claim 1 wherein A^3 is C_{1-4} alkylidene.
28. (original) A compound according to claim 1 wherein A^3 is methylene.
29. (original) A compound according to claim 1 wherein A^3 is a bond.
30. (original) A compound according to claim 1 wherein A^4 is a bond.

USSN 10/662,493

CT2752NP

31. (original) A compound according to claim 1 wherein A^4 is methylene.
32. (original) A compound according to claim 1 wherein A^4 is attached X^1 .
33. (original) A compound according to claim 1 wherein A^4 is attached X.
34. (original) A compound according to claim 1 wherein R^4 is attached X.
35. (original) A compound according to claim 1 wherein R^4 is attached X^1 .
36. (original) A compound according to claim 1 wherein R^4 is cyano or halo and n is 0.
37. (original) A compound according to claim 1 wherein R^1 is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy or cyano; A^1 is C_{1-4} alkylene; R^2 is H or C_{1-3} alkylene; and A^2 is a bond.
38. (original) A compound according to claim 1 wherein R^1 is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A^1 is C_{1-4} alkylene; R^2 is H or C_{1-3} alkylene; and A^2 is a bond.
39. (original) A compound according to claim 1 wherein R^2 is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy or cyano; A^2 is C_{1-4} alkylene; R^1 is H or C_{1-3} alkylene; and A^1 is a bond.
40. (original) A compound according to claim 1 wherein R^2 is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A^2 is C_{1-4} alkylene; R^1 is H or C_{1-3} alkylene; and A^1 is a bond.

USSN 10/662,493

CT2752NP

41. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.
42. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, or -N(H)C(O)O- C_{1-4} alkyl.
43. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, or -O-phenyl.
44. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
45. (original) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.
46. (original) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is N(H)C(O)O- C_{1-4} alkyl.
47. (original) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.
48. (original) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
49. (original) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.
50. (original) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is N(H)C(O)O- C_{1-4} alkyl.
51. (original) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.
52. (original) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.

US 2006/0166249 A1

CT2752NP

53. (original) A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, tetrahydroquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with benzyl.

54. (previously amended) A compound according to claim 1 wherein

A^1 and A^2 are each independently C_{1-4} alkylene or a bond;

A^3 is C_{1-4} alkylene;

A^4 is bond and is attached to X or X^1 ;

X and X^1 are each independently C or CH;

X^2 and X^3 are each CH;

p is 0;

R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy or cyano;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano or benzyl;

R^3 is H or C_{1-4} alkyl;

USSN 10/662,493

CT2752NP

m is 1;

R⁴ is hydrogen, cyano, halo, nitro, C₁₋₃alkyl or C₁₋₃perfluoroalkyl and is attached to X or X¹;

n is 0;

G is N;

G¹ is CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if R¹ is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A¹, then A¹ is C₂₋₄alkylene;

if R² is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A², then A² is C₂₋₄alkylene;

if R¹ is N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, pyrrolidinyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

USSN 10/662,493

CT2752NP

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

if A⁴ or R⁴ are attached to X, then X is C;

if A⁴ or R⁴ are attached to X¹, then X¹ is C.

55. (original) A pharmaceutically acceptable formulation comprising a compound according to claim 1.
56. (previously amended) A method of treating depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, and sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
57. (original) A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
58. (original) A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
59. (original) A compound or pharmaceutically acceptable salt or solvate thereof selected from the group consisting of
- trans*-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - trans*-3-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - trans*-3-(2-ethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - trans*-3-(2-diethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - trans*-3-{2-[(ethyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-5-carbonitrile;
 - trans*-3-(2-pyrrolidin-1-ylmethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - trans*-3-{2-[(benzyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-5-carbonitrile;

USSN 10/662,493

CT2752NP

trans-3-(2-dimethylaminomethyl-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
trans-3-(2-dimethylaminomethyl-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
trans-5-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
trans-5-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
trans-5-(2-pyrrolidin-1-ylmethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
trans-5-(2-ethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
trans-5-{2-[(ethyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-3-carbonitrile;
trans-5-(2-diethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
trans-5-{2-[(benzyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-3-carbonitrile;
trans-5-(2-dimethylaminomethyl-cyclopentyl)-1-methyl-1*H*-indole-3-carbonitrile;
cis-5-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
cis-5-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;
(1*R*, 2*R*)-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
(1*S*, 2*S*)-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;
(+) *trans*-3-[2-(1-dimethylaminoethyl)cyclopentyl]-1*H*-indole-5-carbonitrile;
(-) *trans*-3-[2-(1-dimethylaminoethyl)cyclopentyl]-1*H*-indole-5-carbonitrile;
(+) *trans*-3-[2-(1-dimethylaminopropyl)cyclopentyl]-1*H*-indole-5-carbonitrile;
(-) *trans*-3-[2-(1-dimethylaminopropyl)cyclopentyl]-1*H*-indole-5-carbonitrile;
(1*S*, 2*S*)-[2-(5-iodo-1*H*-indol-3-yl)-cyclopentylmethyl]-dimethylamine;
3-(2-dimethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;
3-(2-methylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;
3-(2-ethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;
3-(2-diethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;
3-[2-(ethyl-methyl-amino)-cyclopentylmethyl]-1*H*-indole-5-carbonitrile;
3-(2-pyrrolidin-1-yl-cyclopentylmethyl)-1*H*-indole-5-carbonitrile; and
3-[2-(benzyl-methyl-amino)-cyclopentylmethyl]-1*H*-indole-5-carbonitrile.